<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20240301011155
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2&amp;v=2.18.0.post9+e462414&amp;fc=20230708114047&amp;utm_source=Chrome&amp;ff=20240301011155" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 01 Mar 2024 06:11:56 +0000</lastbuilddate>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422183/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):502-504. doi: 10.1161/CIRCRESAHA.124.324164. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422183/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422183</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324164>10.1161/CIRCRESAHA.124.324164</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422183</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Felix G Liang</dc:creator>
<dc:creator>Javid Moslehi</dc:creator>
<dc:creator>Richard N Kitsis</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Ponatinib-Induced Cardiomyocyte Toxicity: Dark Side of the Integrated Stress Response</dc:title>
<dc:identifier>pmid:38422183</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324164</dc:identifier>
</item>
<item>
<title>B-Cell Immune Checkpoints Come of Age in Cardio-oncology</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422182/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):569-571. doi: 10.1161/CIRCRESAHA.124.324243. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422182/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422182</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324243>10.1161/CIRCRESAHA.124.324243</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422182</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Alan Gutierrez</dc:creator>
<dc:creator>Javid J Moslehi</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>B-Cell Immune Checkpoints Come of Age in Cardio-oncology</dc:title>
<dc:identifier>pmid:38422182</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324243</dc:identifier>
</item>
<item>
<title>Correction to: Unleashing the Power of Genetics: PLN Ablation, Phospholambanopathies and Evolving Challenges</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422181/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):e16. doi: 10.1161/RES.0000000000000660. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422181/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422181</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000660>10.1161/RES.0000000000000660</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422181</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Correction to: Unleashing the Power of Genetics: PLN Ablation, Phospholambanopathies and Evolving Challenges</dc:title>
<dc:identifier>pmid:38422181</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000660</dc:identifier>
</item>
<item>
<title>Unveiling the Spatiotemporal Diversity of the Endothelium in Development: A Multi-Omics Approach</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422180/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):547-549. doi: 10.1161/CIRCRESAHA.124.324328. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422180/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422180</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324328>10.1161/CIRCRESAHA.124.324328</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422180</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Roy Jung</dc:creator>
<dc:creator>Chinmay M Trivedi</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Unveiling the Spatiotemporal Diversity of the Endothelium in Development: A Multi-Omics Approach</dc:title>
<dc:identifier>pmid:38422180</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324328</dc:identifier>
</item>
<item>
<title>Early Career Research Support From the American Heart Association: to the Second Century and Beyond</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422179/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):478-481. doi: 10.1161/CIRCRESAHA.123.323060. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422179/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422179</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323060>10.1161/CIRCRESAHA.123.323060</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422179</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jessica Pfleger</dc:creator>
<dc:creator>Ronald J Vagnozzi</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Early Career Research Support From the American Heart Association: to the Second Century and Beyond</dc:title>
<dc:identifier>pmid:38422179</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323060</dc:identifier>
</item>
<item>
<title>Preventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422178/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):526-528. doi: 10.1161/CIRCRESAHA.123.323945. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422178/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422178</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323945>10.1161/CIRCRESAHA.123.323945</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422178</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Mathias Mericskay</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Preventing the Fatty Acid-Transporter CD36 From Taking its Toll on the Heart</dc:title>
<dc:identifier>pmid:38422178</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323945</dc:identifier>
</item>
<item>
<title>Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422177/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>CONCLUSION: NMN preserves heart function during lipid overload by preventing v-ATPase disassembly.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):505-525. doi: 10.1161/CIRCRESAHA.123.322910. Epub 2024 Feb 7.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Chronic overconsumption of lipids followed by their excessive accumulation in the heart leads to cardiomyopathy. The cause of lipid-induced cardiomyopathy involves a pivotal role for the proton-pump vacuolar-type H<sup>+</sup>-ATPase (v-ATPase), which acidifies endosomes, and for lipid-transporter CD36, which is stored in acidified endosomes. During lipid overexposure, an increased influx of lipids into cardiomyocytes is sensed by v-ATPase, which then disassembles, causing endosomal de-acidification and expulsion of stored CD36 from the endosomes toward the sarcolemma. Once at the sarcolemma, CD36 not only increases lipid uptake but also interacts with inflammatory receptor TLR4 (Toll-like receptor 4), together resulting in lipid-induced insulin resistance, inflammation, fibrosis, and cardiac dysfunction. Strategies inducing v-ATPase reassembly, that is, to achieve CD36 reinternalization, may correct these maladaptive alterations. For this, we used NAD<sup>+</sup> (nicotinamide adenine dinucleotide)-precursor nicotinamide mononucleotide (NMN), inducing v-ATPase reassembly by stimulating glycolytic enzymes to bind to v-ATPase.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Rats/mice on cardiomyopathy-inducing high-fat diets were supplemented with NMN and for comparison with a cocktail of lysine/leucine/arginine (mTORC1 [mechanistic target of rapamycin complex 1]-mediated v-ATPase reassembly). We used the following methods: RNA sequencing, mRNA/protein expression analysis, immunofluorescence microscopy, (co)immunoprecipitation/proximity ligation assay (v-ATPase assembly), myocellular uptake of [<sup>3</sup>H]chloroquine (endosomal pH), and [<sup>14</sup>C]palmitate, targeted lipidomics, and echocardiography. To confirm the involvement of v-ATPase in the beneficial effects of both supplementations, mTORC1/v-ATPase inhibitors (rapamycin/bafilomycin A1) were administered. Additionally, 2 heart-specific v-ATPase-knockout mouse models (subunits V<sub>1</sub>G1/V<sub>0</sub>d2) were subjected to these measurements. Mechanisms were confirmed in pharmacologically/genetically manipulated cardiomyocyte models of lipid overload.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: NMN successfully preserved endosomal acidification during myocardial lipid overload by maintaining v-ATPase activity and subsequently prevented CD36-mediated lipid accumulation, CD36-TLR4 interaction toward inflammation, fibrosis, cardiac dysfunction, and whole-body insulin resistance. Lipidomics revealed C18:1-enriched diacylglycerols as lipid class prominently increased by high-fat diet and subsequently reversed/preserved by lysine/leucine/arginine/NMN treatment. Studies with mTORC1/v-ATPase inhibitors and heart-specific v-ATPase-knockout mice further confirmed the pivotal roles of v-ATPase in these beneficial actions.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSION: NMN preserves heart function during lipid overload by preventing v-ATPase disassembly.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422177/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422177</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322910>10.1161/CIRCRESAHA.123.322910</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422177</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Shujin Wang</dc:creator>
<dc:creator>Yinying Han</dc:creator>
<dc:creator>Ruimin Liu</dc:creator>
<dc:creator>Mengqian Hou</dc:creator>
<dc:creator>Dietbert Neumann</dc:creator>
<dc:creator>Jun Zhang</dc:creator>
<dc:creator>Fang Wang</dc:creator>
<dc:creator>Yumeng Li</dc:creator>
<dc:creator>Xueya Zhao</dc:creator>
<dc:creator>Francesco Schianchi</dc:creator>
<dc:creator>Chao Dai</dc:creator>
<dc:creator>Lizhong Liu</dc:creator>
<dc:creator>Miranda Nabben</dc:creator>
<dc:creator>Jan F C Glatz</dc:creator>
<dc:creator>Xin Wu</dc:creator>
<dc:creator>Xifeng Lu</dc:creator>
<dc:creator>Xi Li</dc:creator>
<dc:creator>Joost J F P Luiken</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Glycolysis-Mediated Activation of v-ATPase by Nicotinamide Mononucleotide Ameliorates Lipid-Induced Cardiomyopathy by Repressing the CD36-TLR4 Axis</dc:title>
<dc:identifier>pmid:38422177</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322910</dc:identifier>
</item>
<item>
<title>Cardiovascular Consequences of Uremic Metabolites: an Overview of the Involved Signaling Pathways</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422175/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>The crosstalk of the heart with distant organs such as the lung, liver, gut, and kidney has been intensively approached lately. The kidney is involved in (1) the production of systemic relevant products, such as renin, as part of the most essential vasoregulatory system of the human body, and (2) in the clearance of metabolites with systemic and organ effects. Metabolic residue accumulation during kidney dysfunction is known to determine cardiovascular pathologies such as endothelial...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):592-613. doi: 10.1161/CIRCRESAHA.123.324001. Epub 2024 Feb 29.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The crosstalk of the heart with distant organs such as the lung, liver, gut, and kidney has been intensively approached lately. The kidney is involved in (1) the production of systemic relevant products, such as renin, as part of the most essential vasoregulatory system of the human body, and (2) in the clearance of metabolites with systemic and organ effects. Metabolic residue accumulation during kidney dysfunction is known to determine cardiovascular pathologies such as endothelial activation/dysfunction, atherosclerosis, cardiomyocyte apoptosis, cardiac fibrosis, and vascular and valvular calcification, leading to hypertension, arrhythmias, myocardial infarction, and cardiomyopathies. However, this review offers an overview of the uremic metabolites and details their signaling pathways involved in cardiorenal syndrome and the development of heart failure. A holistic view of the metabolites, but more importantly, an exhaustive crosstalk of their known signaling pathways, is important for depicting new therapeutic strategies in the cardiovascular field.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422175/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422175</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324001>10.1161/CIRCRESAHA.123.324001</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422175</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Adelina Curaj</dc:creator>
<dc:creator>Raymond Vanholder</dc:creator>
<dc:creator>Joseph Loscalzo</dc:creator>
<dc:creator>Kaiseng Quach</dc:creator>
<dc:creator>Zhuojun Wu</dc:creator>
<dc:creator>Vera Jankowski</dc:creator>
<dc:creator>Joachim Jankowski</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Cardiovascular Consequences of Uremic Metabolites: an Overview of the Involved Signaling Pathways</dc:title>
<dc:identifier>pmid:38422175</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324001</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422174/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):476-477. doi: 10.1161/RES.0000000000000665. Epub 2024 Feb 29.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422174/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422174</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000665>10.1161/RES.0000000000000665</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422174</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:38422174</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000665</dc:identifier>
</item>
<item>
<title>PIEZO Ion Channels in Cardiovascular Functions and Diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38422173/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>The cardiovascular system provides blood supply throughout the body and as such is perpetually applying mechanical forces to cells and tissues. Thus, this system is primed with mechanosensory structures that respond and adapt to changes in mechanical stimuli. Since their discovery in 2010, PIEZO ion channels have dominated the field of mechanobiology. These have been proposed as the long-sought-after mechanosensitive excitatory channels involved in touch and proprioception in mammals. However,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Mar;134(5):572-591. doi: 10.1161/CIRCRESAHA.123.322798. Epub 2024 Feb 29.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The cardiovascular system provides blood supply throughout the body and as such is perpetually applying mechanical forces to cells and tissues. Thus, this system is primed with mechanosensory structures that respond and adapt to changes in mechanical stimuli. Since their discovery in 2010, PIEZO ion channels have dominated the field of mechanobiology. These have been proposed as the long-sought-after mechanosensitive excitatory channels involved in touch and proprioception in mammals. However, more and more pieces of evidence point to the importance of PIEZO channels in cardiovascular activities and disease development. PIEZO channel-related cardiac functions include transducing hemodynamic forces in endothelial and vascular cells, red blood cell homeostasis, platelet aggregation, and arterial blood pressure regulation, among others. PIEZO channels contribute to pathological conditions including cardiac hypertrophy and pulmonary hypertension and congenital syndromes such as generalized lymphatic dysplasia and xerocytosis. In this review, we highlight recent advances in understanding the role of PIEZO channels in cardiovascular functions and diseases. Achievements in this quickly expanding field should open a new road for efficient control of PIEZO-related diseases in cardiovascular functions.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38422173/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38422173</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.322798>10.1161/CIRCRESAHA.123.322798</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38422173</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Bertrand Coste</dc:creator>
<dc:creator>Patrick Delmas</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>PIEZO Ion Channels in Cardiovascular Functions and Diseases</dc:title>
<dc:identifier>pmid:38422173</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.322798</dc:identifier>
</item>
<item>
<title>Monocytes Release Pro-Cathepsin D to Drive Blood-to-Brain Transcytosis in Diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38420756/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These findings uncover the novel role of circulatory pro-CTSD from monocytes in the pathogenesis of cerebral microvascular lesions in diabetes. The circulatory pro-CTSD is a potential target for the intervention of microvascular complications in diabetes.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Feb 29. doi: 10.1161/CIRCRESAHA.123.323622. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Microvascular complications are the major outcome of type 2 diabetes progression, and the underlying mechanism remains to be determined.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: High-throughput RNA sequencing was performed using human monocyte samples from controls and diabetes. The transgenic mice expressing human CTSD (cathepsin D) in the monocytes was constructed using CD68 promoter. In vivo 2-photon imaging, behavioral tests, immunofluorescence, transmission electron microscopy, Western blot analysis, vascular leakage assay, and single-cell RNA sequencing were performed to clarify the phenotype and elucidate the molecular mechanism.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Monocytes expressed high-level CTSD in patients with type 2 diabetes. The transgenic mice expressing human CTSD in the monocytes showed increased brain microvascular permeability resembling the diabetic microvascular phenotype, accompanied by cognitive deficit. Mechanistically, the monocytes release nonenzymatic pro-CTSD to upregulate caveolin expression in brain endothelium triggering caveolae-mediated transcytosis, without affecting the paracellular route of brain microvasculature. The circulating pro-CTSD activated the caveolae-mediated transcytosis in brain endothelial cells via its binding with low-density LRP1 (lipoprotein receptor-related protein 1). Importantly, genetic ablation of CTSD in the monocytes exhibited a protective effect against the diabetes-enhanced brain microvascular transcytosis and the diabetes-induced cognitive impairment.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These findings uncover the novel role of circulatory pro-CTSD from monocytes in the pathogenesis of cerebral microvascular lesions in diabetes. The circulatory pro-CTSD is a potential target for the intervention of microvascular complications in diabetes.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38420756/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38420756</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.323622>10.1161/CIRCRESAHA.123.323622</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38420756</guid>
<pubDate>Thu, 29 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Dan Zhao</dc:creator>
<dc:creator>Zeng-Kang Huang</dc:creator>
<dc:creator>Yu Liang</dc:creator>
<dc:creator>Zhi-Jun Li</dc:creator>
<dc:creator>Xue-Wei Zhang</dc:creator>
<dc:creator>Kun-Hang Li</dc:creator>
<dc:creator>Hao Wu</dc:creator>
<dc:creator>Xu-Dong Zhang</dc:creator>
<dc:creator>Chen-Sheng Li</dc:creator>
<dc:creator>Dong An</dc:creator>
<dc:creator>Xue Sun</dc:creator>
<dc:creator>Ming-Xin An</dc:creator>
<dc:creator>Jun-Xiu Shi</dc:creator>
<dc:creator>Yi-Jun Bao</dc:creator>
<dc:creator>Li Tian</dc:creator>
<dc:creator>Di-Fei Wang</dc:creator>
<dc:creator>An-Hua Wu</dc:creator>
<dc:creator>Yu-Hua Chen</dc:creator>
<dc:creator>Wei-Dong Zhao</dc:creator>
<dc:date>2024-02-29</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Monocytes Release Pro-Cathepsin D to Drive Blood-to-Brain Transcytosis in Diabetes</dc:title>
<dc:identifier>pmid:38420756</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.323622</dc:identifier>
</item>
<item>
<title>Novel drug therapies for atrial fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Feb 28. doi: 10.1038/s41569-024-01004-2. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418746</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01004-2>10.1038/s41569-024-01004-2</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418746</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Felix Wiedmann</dc:creator>
<dc:creator>Constanze Schmidt</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Novel drug therapies for atrial fibrillation</dc:title>
<dc:identifier>pmid:38418746</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01004-2</dc:identifier>
</item>
<item>
<title>Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418013/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):e89. doi: 10.1016/j.jacc.2023.12.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418013/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418013</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.030>10.1016/j.jacc.2023.12.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418013</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian Claggett</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</dc:title>
<dc:identifier>pmid:38418013</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.030</dc:identifier>
</item>
<item>
<title>Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418012/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):e87. doi: 10.1016/j.jacc.2023.09.838.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418012/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418012</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.09.838>10.1016/j.jacc.2023.09.838</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418012</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Yuzuru Ohshiro</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Rethinking eGFR Comparisons in SGLT2 Inhibitor Research</dc:title>
<dc:identifier>pmid:38418012</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.09.838</dc:identifier>
</item>
<item>
<title>Correction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418011/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):959. doi: 10.1016/j.jacc.2024.01.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418011/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418011</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.020>10.1016/j.jacc.2024.01.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418011</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Correction</dc:title>
<dc:identifier>pmid:38418011</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.020</dc:identifier>
</item>
<item>
<title>Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418010/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):956-958. doi: 10.1016/j.jacc.2023.12.029.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418010/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418010</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.029>10.1016/j.jacc.2023.12.029</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418010</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Malene K Hansen</dc:creator>
<dc:creator>Kevin K W Olesen</dc:creator>
<dc:creator>Christine Gyldenkerne</dc:creator>
<dc:creator>Pernille G Thrane</dc:creator>
<dc:creator>Nina Stødkilde-Jørgensen</dc:creator>
<dc:creator>Martin B Mortensen</dc:creator>
<dc:creator>Michael Maeng</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Eligibility for and Preventive Potential of Semaglutide in Overweight and Obese Patients With Myocardial Infarction</dc:title>
<dc:identifier>pmid:38418010</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.029</dc:identifier>
</item>
<item>
<title>The Legends Colloquium: A Conversation Between Eugene Braunwald and Valentin Fuster</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418009/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):951-955. doi: 10.1016/j.jacc.2024.01.019.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418009/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418009</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.019>10.1016/j.jacc.2024.01.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418009</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Martin E Goldman</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Legends Colloquium: A Conversation Between Eugene Braunwald and Valentin Fuster</dc:title>
<dc:identifier>pmid:38418009</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.019</dc:identifier>
</item>
<item>
<title>Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418008/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular conditions that frequently coexist. Among patients with HF, more than one-half also have AF. Both are associated with significant morbidity and mortality. Moreover, the prevalence of each is increasing globally, and this trend is expected to continue owing to an aging population and increased life expectancy. Diagnosis of AF in a patient with HF is associated with greater symptom burden, more frequent hospitalizations, and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):932-950. doi: 10.1016/j.jacc.2023.12.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Atrial fibrillation (AF) and heart failure (HF) are common cardiovascular conditions that frequently coexist. Among patients with HF, more than one-half also have AF. Both are associated with significant morbidity and mortality. Moreover, the prevalence of each is increasing globally, and this trend is expected to continue owing to an aging population and increased life expectancy. Diagnosis of AF in a patient with HF is associated with greater symptom burden, more frequent hospitalizations, and a worse prognosis. Guideline-directed medical therapy (GDMT) for HF can affect the incidence of AF. Once present, AF can influence the efficacy of some components of GDMT for HF. In this review, we discuss the effect of GDMT for HF across the spectrum of ejection fraction on prevention of AF as well as the benefit of GDMT in patients with vs without AF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418008/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418008</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.033>10.1016/j.jacc.2023.12.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418008</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Joshua D Newman</dc:creator>
<dc:creator>Eileen O'Meara</dc:creator>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Gianluigi Savarese</dc:creator>
<dc:creator>Patricia R Kelly</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Patrizio Lancellotti</dc:creator>
<dc:creator>Stephen S Gottlieb</dc:creator>
<dc:creator>Zainab Samad</dc:creator>
<dc:creator>Alanna A Morris</dc:creator>
<dc:creator>Nihar R Desai</dc:creator>
<dc:creator>Giuseppe M C Rosano</dc:creator>
<dc:creator>John R Teerlink</dc:creator>
<dc:creator>Clara Saldarriaga Giraldo</dc:creator>
<dc:creator>JoAnn Lindenfeld</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Implications of Atrial Fibrillation for Guideline-Directed Therapy in Patients With Heart Failure: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:38418008</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.033</dc:identifier>
</item>
<item>
<title>Anemia and Sex Disparity in CABG Mortality: In Search of a Grand Unified Theory</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418007/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):929-931. doi: 10.1016/j.jacc.2024.01.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418007/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418007</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.005>10.1016/j.jacc.2024.01.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418007</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Thomas A Schwann</dc:creator>
<dc:creator>Daniel T Engelman</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Anemia and Sex Disparity in CABG Mortality: In Search of a Grand Unified Theory</dc:title>
<dc:identifier>pmid:38418007</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.005</dc:identifier>
</item>
<item>
<title>Intraoperative Anemia Mediates Sex Disparity in Operative Mortality After Coronary Artery Bypass Grafting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418006/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: The association of female sex with increased CABG operative mortality is mediated to a large extent by intraoperative anemia. Avoiding nadir intraoperative hematocrit values below 22.0% may reduce sex differences in CABG operative mortality.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):918-928. doi: 10.1016/j.jacc.2023.12.032.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Women undergoing coronary artery bypass grafting (CABG) have higher operative mortality than men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to evaluate the relationship between intraoperative anemia (nadir intraoperative hematocrit), CABG operative mortality, and sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This was a cohort study of 1,434,225 isolated primary CABG patients (344,357 women) from the Society of Thoracic Surgeons Adult Cardiac Surgery Database (2011-2022). The primary outcome was operative mortality. The attributable risk (AR) (the risk-adjusted strength of the association of female sex with CABG outcomes) for the primary outcome was calculated. Causal mediation analysis derived the total effect of female sex on operative mortality risk and the proportion of that effect mediated by intraoperative anemia.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Women had lower median nadir intraoperative hematocrit (22.0% [Q1-Q3: 20.0%-25.0%] vs 27.0% [Q1-Q3: 24.0%-30.0%], standardized mean difference 97.0%) than men. Women had higher operative mortality than men (2.8% vs 1.7%; P &lt; 0.001; adjusted OR: 1.36; 95% CI: 1.30-1.41). The AR of female sex for operative mortality was 1.21 (95% CI: 1.17-1.24). After adjusting for nadir intraoperative hematocrit, AR was reduced by 43% (1.12; 95% CI: 1.09-1.16). Intraoperative anemia mediated 38.5% of the increased mortality risk associated with female sex (95% CI: 32.3%-44.7%). Spline regression showed a stronger association between operative mortality and nadir intraoperative hematocrit at hematocrit values &lt;22.0% (P &lt; 0.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: The association of female sex with increased CABG operative mortality is mediated to a large extent by intraoperative anemia. Avoiding nadir intraoperative hematocrit values below 22.0% may reduce sex differences in CABG operative mortality.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418006/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418006</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.12.032>10.1016/j.jacc.2023.12.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418006</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Lamia Harik</dc:creator>
<dc:creator>Robert H Habib</dc:creator>
<dc:creator>Arnaldo Dimagli</dc:creator>
<dc:creator>Mohamed Rahouma</dc:creator>
<dc:creator>Roberto Perezgrovas-Olaria</dc:creator>
<dc:creator>Giovanni Jr Soletti</dc:creator>
<dc:creator>Talal Alzghari</dc:creator>
<dc:creator>Kevin R An</dc:creator>
<dc:creator>Lisa Q Rong</dc:creator>
<dc:creator>Sigrid Sandner</dc:creator>
<dc:creator>C Noel Bairey-Merz</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Leonard Girardi</dc:creator>
<dc:creator>Mario Gaudino</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Intraoperative Anemia Mediates Sex Disparity in Operative Mortality After Coronary Artery Bypass Grafting</dc:title>
<dc:identifier>pmid:38418006</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.12.032</dc:identifier>
</item>
<item>
<title>Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38418005/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240301011155&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Mar 5;83(9):915-917. doi: 10.1016/j.jacc.2024.01.009.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38418005/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240301011155&v=2.18.0.post9+e462414">38418005</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.01.009>10.1016/j.jacc.2024.01.009</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38418005</guid>
<pubDate>Wed, 28 Feb 2024 06:00:00 -0500</pubDate>
<dc:creator>Jacob A Udell</dc:creator>
<dc:creator>David W J Armstrong</dc:creator>
<dc:date>2024-02-28</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Targeting the Natriuretic Peptide System to Improve Outcomes: PARADISE Lost or Found</dc:title>
<dc:identifier>pmid:38418005</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.01.009</dc:identifier>
</item>





























</channel>
</rss>